Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    82.98
    +1.63 (+2.00%)
     
  • Gold

    2,241.00
    +28.30 (+1.28%)
     
  • Silver

    24.99
    +0.24 (+0.96%)
     
  • EUR/USD

    1.0790
    -0.0040 (-0.37%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2621
    -0.0017 (-0.14%)
     
  • USD/JPY

    151.3920
    +0.1460 (+0.10%)
     
  • Bitcoin USD

    70,686.17
    +1,606.37 (+2.33%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEVTM) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 5th Annual HealthCONx Virtual Conference on Tuesday, November 29, 2022 at 3:55 p.m. Eastern Time.

A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com


Advertisement